Glaukos Reports Strong Preliminary Q4 and Full Year 2025 Net Sales, Reaffirms 2026 Guidance
summarizeSummary
Glaukos Corporation announced robust preliminary net sales for Q4 and full year 2025, with significant year-over-year growth, and reaffirmed its positive revenue guidance for 2026.
check_boxKey Events
-
Strong Q4 2025 Net Sales
Preliminary net sales reached approximately $143 million, marking a 36% increase compared to Q4 2024.
-
Robust Full Year 2025 Performance
Full year preliminary net sales were approximately $507 million, up 32% from 2024.
-
iDose TR Contribution
The iDose TR product contributed significantly, with approximately $45 million in Q4 and $136 million for the full year in US Glaucoma net sales.
-
2026 Guidance Reaffirmed
The company reaffirmed its full year 2026 net sales guidance range of $600 million to $620 million.
auto_awesomeAnalysis
The preliminary results indicate strong operational performance, particularly with a 36% increase in Q4 net sales and a 32% increase for the full year 2025. The reaffirmation of 2026 revenue guidance, coupled with a healthy cash position and no debt, provides a positive outlook for the company's continued growth and financial stability. Investors should view these results as a strong indicator of execution across key commercial and development initiatives.
At the time of this filing, GKOS was trading at $96.97 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $73.16 to $163.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.